NOTCH1 and non-small cell lung carcinoma: Recent studies have shown that co-occurring mutations in Notch1–3 and homologous recombination repair (HR) genes are associated with increased immunotherapy efficacy in patients with advanced NSCLC (Mazzotta et al., 2020).